06/05/2016 20:26:37 1-888-992-3836 (toll free) Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
05/05/20167:30AMBWModern Family Star Eric Stonestreet & His Mom, a Two Time Cancer Survivor, Join Forces to Raise Awareness of Immuno-Oncology ...
Ready. Raise. Rise. creates a social movement to honor cancer patients and caregivers and helps provide charitable donations to advocacy organizations Bristol-Myers Squibb and Eric Stonestreet call on anyone touched by cancer to raise and share a virtual flag to support the cancer community The Ready. Raise. Rise. campaign... More...>>
04/28/20166:10PMDJNDrugmakers Place Big Bets on Cancer Medicines
Despite a growing outcry over the rising cost of cancer treatments, drugmakers are placing multibillion-dollar bets on new medicines they expect will command premium prices and generate big sales. France's Sanofi SA said Thursday it made an unsolicited, $9.3 billion offer to purchase San Francisco-based Medivation... More...>>
04/28/20167:28AMDJNBristol-Myers Revenue Rises 8.7%,
By Tess Stynes Bristol-Myers Squibb Co. said its first-quarter revenue rose a better-than-expected 8.7%, boosted by the continued expansion of the pharmaceutical company's Opdivo cancer immunotherapy and growth of other key drugs. The pharmaceutical company's adjusted per-share earnings, excluding certain one-time... More...>>
04/28/20166:59AMBWBristol-Myers Squibb Reports First Quarter Financial Results
Increases First Quarter Revenues 9% to $4.4 Billion Posts First Quarter GAAP EPS of $0.71 and Non-GAAP EPS of $0.74 Achieves Significant European Regulatory Milestones in Immuno-Oncology Opdivo Approved for Previously Treated Advanced Renal Cell Carcinoma Expanded Use of Opdivo to Include Previously Treated Metastatic... More...>>
04/27/201610:00AMBWBristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4, 2016, in Boston. Murdo Gordon, senior vice president, Head of Worldwide Markets, will answer questions about the company at 11:20 a.m. EDT. Investors and the general public are invited to... More...>>
04/25/20166:59AMBWBristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food & Drug Administration ...
Designation based on results of Phase 3 study, CheckMate -141, in which Opdivo met its primary endpoint of overall survival, versus three standard of care options in this patient population Designation signals the urgent need for new treatment approaches in recurrent or metastatic squamous cell carcinoma of the head and... More...>>
04/22/20166:44AMDJNChina Eases Path for Foreign Drugmakers' Hepatitis C Treatments
SHANGHAI-- China will grant four global drug companies priority-review status to launch groundbreaking new hepatitis C treatments in China, a rare move to open the lucrative market to foreign players. China's Food and Drug Administration expedites domestic drug applications to encourage innovation. But its lengthy... More...>>
04/19/20169:30AMBWFirst Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus In...
Opdivo is the first and only PD-1 inhibitor to demonstrate a statistically significant improvement in overall survival compared to three standard of care options in this setting, based on CheckMate -141 Data from CheckMate -141 showed survival benefit with Opdivo in this overall population, regardless of PD-L1 expression... More...>>
04/17/20168:50PMDJNBristol's Opdivo Shows Benefits in Cancer Immunotherapy Trial
More than one-third of advanced melanoma patients treated in a study of Bristol-Myers Squibb Co.'s Opdivo have survived at least five years, researchers said, providing fresh evidence of the durable benefit cancer immunotherapy agents have for some patients. The study followed 107 patients who were enrolled in an... More...>>
04/17/20165:34PMDJNBristol's Opdivo Shows Benefits in Cancer Immunotherapy Trial
By Ron Winslow More than one-third of advanced melanoma patients treated in a study of Bristol-Myers Squibb Co.'s Opdivo have survived at least five years, researchers said, providing fresh evidence of the durable benefit cancer immunotherapy agents have for some patients. The study followed 107 patients who were... More...>>
04/17/20163:15PMBWFirst Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showe...
Opdivo and Yervoy combination regimen showed two-year overall survival rate of 69% in an exploratory analysis of patients with BRAF wild-type advanced melanoma in CheckMate -069; with 22% of patients achieving a complete response Safety profile of the combination regimen from CheckMate -069 was consistent with previously... More...>>
04/14/20169:20AMDJNFDA to Review Bristol-Myers's Opdivo for Hodgkin Lymphoma
The U.S. Food and Drug Administration has accepted Bristol-Myers Squibb Co.'s supplemental biologics license application to expand the use of its cancer drug Opdivo to patients who are facing difficult-to-treat variations of Hodgkin lymphoma, the pharmaceutical company said Thursday. Bristol-Myers wants to use Opdivo... More...>>
04/14/20169:12AMDJNFDA to Review Bristol-Myers's Opdivo for Hodgkin Lymphoma
By Austen Hufford The U.S. Food and Drug Administration has accepted Bristol-Myers Squibb Co.'s supplemental biologics license application to expand the use of its cancer drug Opdivo to patients who are facing difficult-to-treat variations of Hodgkin lymphoma, the pharmaceutical company said Thursday. Bristol-Myers... More...>>
04/14/20166:59AMBWU.S. Food & Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Supplemental Biologics License Applicati...
Opdivo has potential to become first PD-1 inhibitor approved for a hematological malignancy in United States Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA), which seeks to expand the use of Opdivo to... More...>>
04/06/201611:45AMBWEuropean Commission Approves Bristol-Myers Squibb’s Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma
Opdivo is the first and only PD-1 inhibitor approved to treat advanced renal cell carcinoma patients who have received prior therapy Opdivo is the first-ever agent to demonstrate a significant improvement in overall survival, the primary endpoint, in advanced renal cell carcinoma patients who have received prior therapy... More...>>
04/06/201611:12AMBWEuropean Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-S...
This approval expands Opdivo’s existing lung cancer indication in previously treated metastatic squamous NSCLC to include the non-squamous patient population, which together represents 85% of lung cancer cases Opdivo is the only PD-1 inhibitor approved for a broad range of patients with previously treated metastatic... More...>>
04/01/20164:15PMBWBristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has completed the previously announced planned acquisition of Padlock Therapeutics, Inc. The transaction includes full rights to Padlock’s Protein/Peptidyl Arginine Deiminase inhibitor discovery program focused on the development of potentially transformational... More...>>
04/01/201612:30PMDJNSamsung Nears European Approval for Near-Replica Version of Arthritis Drug
SEOUL—The Samsung Group's drug-development arm said it is on track to win European regulatory approval for a knockoff version of Johnson & Johnson's blockbuster rheumatoid arthritis drug Remicade, marking a second straight victory for the South Korean conglomerate's fledgling ambitions in biologic... More...>>
04/01/201611:52AMBWBristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Tr...
First combination of two Immuno-Oncology agents in advanced melanoma to receive positive CHMP opinion, based on efficacy and safety data from two trials, CheckMate -067 and CheckMate -069 Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended... More...>>
03/30/20164:15PMBWEuropean Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Classi...
Opdivo has potential to become first PD-1 inhibitor approved in a hematological malignancy in European Union Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated a type II variation application, which seeks to extend the current indications for Opdivo to include the... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20160507 00:26:39